JOAO CARLOS PAPATERRA LIMONGI
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
7 resultados
Resultados de Busca
Agora exibindo 1 - 7 de 7
- Wilson's disease(2013) LIMONGI, Joao Carlos Papaterra
- Movement Disorders in Brazil: the seminal contributions of Luiz Augusto Franco de Andrade and Egberto Reis Barbosa(2021) TEIVE, Helio Afonso Ghizoni; FERRAZ, Henrique Ballalai; LIMONGI, Joao Carlos Papaterra; FRANKLIN, Gustavo Leite; CARDOSO, Francisco Eduardo CostaThe major advances in the area of movement disorders in Brazil in recent years were driven by the work of Luiz Augusto Franco de Andrade and Egberto Reis Barbosa. This historical review describes the contributions made by these researchers, physicians, and educators to the development of this field in Brazil.
- Roberto Melaragno's scientific contributions to Brazilian Neurology(2021) LIMONGI, Joao Carlos Papaterra; LIMA, Plinio Marcos Garcia; SILVA, Sonia Maria Cesar de Azevedo; FERREIRA, Matheus Gomes; BARBOSA, Egberto Reis; TEIVE, Helio Afonso GhizoniRoberto Melaragno Filho, an associate professor of neurology at the School of Medicine of Universidade de Sao Paulo and head of the neurology service at Hospital do Servidor Publico Estadual Francisco Morato Oliveira (HSPE-FMO), had a significant scientific career. He is recognized as a reference in the 20th century Brazilian neurology in addition to having a notable international career.
- Quality of life in Parkinson's disease(2017) LIMONGI, Joao Carlos Papaterra
- Neurodegeneration with brain iron accumulation(2016) LIMONGI, Joao Carlos Papaterra
- Speech disorders did not correlate with age at onset of Parkinson's disease(2016) DIAS, Alice Estevo; BARBOSA, Maira Tonidandel; LIMONGI, Joao Carlos Papaterra; BARBOSA, Egberto ReisObjective: To compare speech articulation in patients according to age at onset of the disease. Methods: Fifty patients was divided into two groups: Group I consisted of 30 patients with age at onset between 40 and 55 years; Group II consisted of 20 patients with age at onset after 65 years. All patients were evaluated based on the Unified Parkinson's Disease Rating Scale scores, Hoehn and Yahr scale and speech evaluation by perceptual and acoustical analysis. Results: There was no statistically significant difference between the two groups regarding neurological involvement and speech characteristics. Correlation analysis indicated differences in speech articulation in relation to staging and axial scores of rigidity and bradykinesia for middle and late-onset. Conclusions: Impairment of speech articulation did not correlate with age at onset of disease, but was positively related with disease duration and higher scores in both groups.
- How I treat Parkinson's disease(2022) BARBOSA, Egberto Reis; LIMONGI, Joao Carlos Papaterra; CHIEN, Hsin Fen; BARBOSA, Pedro Melo; TORRES, Marcela Reuter CarreraBackground: Parkinson's disease (PD) is a complex neurodegenerative condition. Treatment strategies through all stages of disease progression could affect quality of life and influence the development of future complications, making it crucial for the clinician to be on top of the literature. Objective: This paper reviews the current treatment of PD, from early to advanced stages. Methods: A literature review was conducted focusing on the treatment of PD, in the different stages of progression. Results: Every individual with a new diagnosis of PD should be encouraged to start exercising regularly. In the early stage, treatment should focus on using the lowest dose of levodopa or combination therapy that provides maximum functional capacity, and does not increase the risk of complications, such as peak dose dyskinesias and impulse control disorders. At the moderate and advanced stages, motor fluctuations and complications of treatment dominate the picture, making quality of life one important issue. Rehabilitation programs can improve motor symptoms and should be offered to all patients at any stage of disease progression. Conclusion: Many factors need to be considered when deciding on the best treatment strategy for PD, such as disease progression, presence of risk factors for motor and behavioral complications, potential side effects from dopaminergic therapy and phenotypical variabilities. Treatment should focus on functional capacity and quality of life throughout the whole disease course.